Plus Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Lisa Levin
Insiders at Plus Therapeutics, Blend Labs, and Bimini Capital Management have recently purchased shares in their respective companies. Plus Therapeutics Director Howard Clowes acquired 6,993 shares at an average price of $1.43. Blend Labs Head of Finance and Admin. Amir Jafari acquired 14,369 shares at an average price of $1.19. Bimini Capital Management CFO G. Hunter Haas IV acquired 9,354 shares at an average price of $0.93.
September 18, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blend Labs Head of Finance and Admin. Amir Jafari acquired 14,369 shares at an average price of $1.19. The company recently reported better-than-expected Q2 financial results and issued Q3 revenue guidance.
Insider buying often indicates confidence in a company's prospects. The recent positive financial results and Q3 guidance could also be a positive development for Blend Labs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bimini Capital Management CFO G. Hunter Haas IV acquired 9,354 shares at an average price of $0.93. The company recently posted Q2 net income of $0.3 million.
Insider buying often indicates confidence in a company's prospects. The recent Q2 earnings report could also be a positive development for Bimini Capital Management.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Plus Therapeutics Director Howard Clowes acquired 6,993 shares at an average price of $1.43. The company recently announced a licensing agreement with Biocept.
Insider buying often indicates confidence in a company's prospects. The recent licensing agreement with Biocept could also be a positive development for Plus Therapeutics.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100